Publications by authors named "Sabina B Aleixo"
Purpose: This study aimed to describe the demographic and clinical characteristics of cancer patients with COVID-19, exploring factors associated with adverse outcomes.
Patients And Methods: This retrospective cohort study methodically extracted and curated data from electronic medical records (EMRs) of numerous healthcare institutions on cancer patients diagnosed with a confirmed SARS-CoV-2 infection between May 2020 and August 2021, to identify risk factors linked to extended hospitalization and mortality. The retrieved information encompassed the patients' demographic and clinical characteristics, including the incidence of prolonged hospitalization, acute complications, and COVID-19-related mortality.
Background: Data are scarce regarding real-world health care resource use (HCRU) for non-small cell lung cancer (NSCLC). An understanding of current clinical practices and HCRU is needed to provide a benchmark for rapidly evolving NSCLC management recommendations and therapeutic options. The objective of this study was to describe real-world HCRU for patients with advanced NSCLC.
View Article and Find Full Text PDFObjectives:: To compare the efficacy and safety of two filgrastim formulations for controlling chemotherapy-induced neutropenia and to evaluate the non-inferiority of the test drug relative to the originator.
Methods:: This phase III non-inferiority study had a randomized, multicenter, and open-label design. The patients were randomized at a ratio of 1:1 with a follow-up period of 6 weeks for each patient.
Article Synopsis
- Chemotherapy is the standard treatment for locally advanced HER2-positive breast cancer, but using targeted therapies like afatinib may offer more benefits compared to traditional options like trastuzumab and lapatinib.
- In a study of treatment-naive patients, those receiving afatinib showed a comparable response rate to trastuzumab and lapatinib, but with a higher incidence of drug-related side effects.
- Overall, afatinib showed promising clinical activity with a safety profile typical of other similar targeted therapies, indicating it could be a viable alternative in neoadjuvant therapy for this type of breast cancer.